Novartis Pharma AG is discontinuing development of a long-acting injectable version of Fanapt (iloperidone) reported Vanda Pharmaceuticals in a securities...
The FDA has approved Vanda Pharma's supplemental New Drug Application (sNDA) for Fanapt (iloperidone) modifying and expanding the prescribing information...
The FDA has accepted for review Vanda's filing of a supplemental New Drug Application (sNDA) for Fanapt (iloperidone) seeking approval...
Vanda Pharmaceuticals Inc announced that the FDA has approved Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.